MGCD0103 (Mocetinostat)
Catalog No. A10586
MGCD0103 (Mocetinostat)是一种苯甲酰胺组蛋白脱乙酰基酶抑制剂,主要抑制组蛋白脱乙酰基酶1(HDAC1),但也抑制HDAC2,HDAC3和HDAC11。
- Mari Ishigami-Yuasa, .et al. Class IIb HDAC Inhibition Enhances the Inhibitory Effect of Am80, a Synthetic Retinoid, in Prostate Cancer, Biol Pharm Bull, 2019, 42, 448-452
- Guang Bai, .et al. Chapter 1 - Epigenetic Tools in Chronic Pain Studies, Epigenetics of Chronic Pain, 2019, Pages 1-48
Catalog Num | A10586 |
---|---|
M. Wt | 396.4 |
Formula | C23H20N6O |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 726169-73-9 |
Synonyms | MGCD-0103 |
SMILES | C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4 |
MGCD0103 (Mocetinostat)是一种苯甲酰胺组蛋白脱乙酰基酶抑制剂,主要抑制组蛋白脱乙酰基酶1(HDAC1),但也抑制HDAC2,HDAC3和HDAC11。
Targets
Target | Value |
---|---|
HDAC1 | IC50: 0.15μM |
HDAC2 | IC50: 0.29μM |
HDAC11 | IC50: 0.59μM |
HDAC3 | IC50: 1.66μM |
HDAC4 | IC50: >10μM |
HDAC5 | IC50: >10μM |
HDAC6 | IC50: >10μM |
HDAC7 | IC50: >10μM |
HDAC8 | IC50: >10μM |
In vitro (25°C) | DMSO | 12 mg/mL (30.27 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 30% PEG400+0.5% Tween80+5% Propylene glycol | 28 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 25.23 mL | 126.14 mL | 252.27 mL |
0.5 mM | 5.05 mL | 25.23 mL | 50.45 mL |
1 mM | 2.52 mL | 12.61 mL | 25.23 mL |
5 mM | 0.5 mL | 2.52 mL | 5.05 mL |
*The above data is based on the productmolecular weight 396.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.